Design and characterization
暂无分享,去创建一个
[1] M. Lethem,et al. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. , 1990, The European respiratory journal.
[2] N. Hodges,et al. Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate , 1991, Antimicrobial Agents and Chemotherapy.
[3] F. Ratjen,et al. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis , 2001, The Lancet.
[4] L. Delattre,et al. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[5] J. Emerson,et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis , 2007, Pediatric pulmonology.
[6] Xiuli Wang,et al. Solid lipid nanoparticles for pulmonary delivery of insulin. , 2008, International journal of pharmaceutics.
[7] D. Geller,et al. New aerosol delivery devices for cystic fibrosis. , 2009, Respiratory care.
[8] R. Neale,et al. Development of the First Inhaled Antibiotic for the Treatment of Cystic Fibrosis , 2010, Science Translational Medicine.
[9] A. Zychlinsky,et al. Neutrophil Elastase Enhances Sputum Solubilization in Cystic Fibrosis Patients Receiving DNase Therapy , 2011, PloS one.
[10] Anders Folkesson,et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective , 2012, Nature Reviews Microbiology.
[11] P. Belliveau,et al. Inhaled Aztreonam Lysine for Cystic Fibrosis Pulmonary Disease–Related Outcomes , 2012, The Annals of pharmacotherapy.
[12] N. Høiby,et al. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. , 2012, FEMS immunology and medical microbiology.
[13] J. Elborn,et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[14] J. Varshosaz,et al. Biodistribution of Amikacin Solid Lipid Nanoparticles after Pulmonary Delivery , 2013, BioMed research international.
[15] R. Hartmann,et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[16] Garry R. Cutting,et al. Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.
[17] B. Tümmler,et al. Origins of cystic fibrosis lung disease. , 2015, The New England journal of medicine.